ENTITY
Ascletis Pharma Inc

Ascletis Pharma Inc (1672 HK)

81
Analysis
Health CareChina
Ascletis Pharma Inc. operates as a biotechnology company. The Company develops and discovers anti-viral drugs to address unmet medical needs in anti-viral, cancer, and fatty liver disease. Ascletis Pharma offers its services worldwide.
more
02 Dec 2019 16:07

Hong Kong Buyback Weekly: Xiaomi Is Back

Hong Kong Exchange publishes share repurchases by listed companies on a daily basis. In our weekly note, we will provide statistics on top...

Logo
362 Views
Share
bullishAlphamab Co Ltd
18 Nov 2019 16:57

Alphamab (康宁杰瑞) Pre-IPO: Promising Readings from PHIP Updates

Alphamab obtained approval from HKSE last week and started pre-marketing for its USD 200-300m deal this week. In our previous notes, we covered the...

Logo
539 Views
Share
bullishSmartkarma
12 Sep 2019 15:33

Hong Kong IPO Analytics - Regular Cornerstone Investors and Track Record

At the beginning of this year, we at Aequitas Research, wrote on IPO analytics of deals across Asia-Pacific from 2016 to 2018. If you have not read...

Logo
1.1k Views
Share
17 Jul 2019 09:52

Tasly Biopharm (天士力生物) IPO: Visible Growth from Approved Drug but Lacks Blockbusters

Tasly Biopharm, a biologics R&D platform spin-off from A-share listed Tasly Pharmaceutical Group (600535 CH), is looking to raise up to USD 1...

Logo
1.1k Views
Share
15 Jan 2019 09:06

Last Week in GER IPO Research: Leong Hup, China Tobacco, Futu and Weimob

We slide into 2019 with GER's recap of our latest IPO research. This week, we talk chicken as Arun initiates on the IPO Malaysian poultry producer...

Logo
754 Views
Share
x